| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The de novo synthesis of NADPH tetrasodium salt is conducted by NAD kinase (NADK), which catalyzes the phosphorylation of NAD+ to generate NADP+. NADPH tetrasodium salt is predominantly involved in catabolic reactions, while NADPH tetrasodium salt is mainly involved in cellular antioxidant effects and anabolic reactions. Glutathione reductase (GR) employs NADPH tetrasodium salt to decrease oxidized glutathione (GSSG) to GSH[1]. The rate of regeneration of NADPH tetrasodium salt is often the rate-limiting step in overproduction of the desired chemical while sustaining strong cell growth [2]. NADPH tetrasodium homeostasis is regulated by numerous signaling pathways and multiple metabolic enzymes that undergo adaptive alterations in cancer cells. Metabolic reprogramming by NADPH tetrasodium salt makes cancer cells highly dependent on the antioxidant activity of this metabolic network and more vulnerable to oxidative stress [3]. NADPH tetrasodium salt is a key intracellular reducing agent required for the removal of lipid hydroperoxides. In fact, NADPH tetrasodium salt levels are a diagnostic of ferroptosis susceptibility in several cancer cell lines [4].
|
|---|---|
| References |
[1]. Tedeschi PM, et al. NAD+ Kinase as a Therapeutic Target in Cancer. Clin Cancer Res. 2016;22(21):5189-5195.
[2]. Ng CY, F et al. Rational design of a synthetic Entner-Doudoroff pathway for improved and controllable NADPH regeneration. Metab Eng. 2015;29:86-96. [3]. Ju HQ, Lin JF, et al. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Target Ther. 2020;5(1):231. Published 2020 Oct 7. [4]. Stockwell BR, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273-285. |
| Molecular Formula |
C21H26N7O17P3
|
|---|---|
| Molecular Weight |
741.3891
|
| CAS # |
2646-71-1
|
| Related CAS # |
NADPH tetracyclohexanamine;100929-71-3
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
P(=O)([O-])([O-])O[C@@]1([H])[C@]([H])(N2C([H])=NC3=C(N([H])[H])N=C([H])N=C23)O[C@]([H])(C([H])([H])OP(=O)([O-])OP(=O)([O-])OC([H])([H])[C@]2([H])[C@]([H])([C@]([H])([C@]([H])(N3C([H])=C([H])C([H])([H])C(C(N([H])[H])=O)=C3[H])O2)O[H])O[H])[C@@]1([H])O[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 35 mg/mL (~42.00 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (120.00 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3488 mL | 6.7441 mL | 13.4882 mL | |
| 5 mM | 0.2698 mL | 1.3488 mL | 2.6976 mL | |
| 10 mM | 0.1349 mL | 0.6744 mL | 1.3488 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
